Owen Barry Pharmaceuticals began operations in 2014 to undertake the research and development of a new class of molecules that show promise for the treatment of epilepsy and brain injury related seizures.
Epilepsy is a chronic neurological spectrum disorder affecting nearly 65 million people worldwide and is characterized by recurrent and often debilitating seizures. More than 30% are or become refractory to current medications.
A seizure is abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and / or involuntary muscle movements.
Our Drug Pipeline
OB Pharmaceuticals has advanced the pre-clinical development of new chemical entities or “NCE's” that act at a key target in the brain to prevent the abnormal electrical activity in neural networks that leads to seizures. They show promise to not only stop seizures but also the potential to prevent epilepsy from occurring in the first place. These properties combined with low or no side effects, makes lead candidates one of the most promising new preclinical therapeutics currently under development.
Changing the world for generations to come
Matthew experienced his first seizure in 2012 when he was five at summer camp. He spent the next 18 months in hospitals and to this day, no one has been able to definitively diagnose the source of his neuropathology. On a "good day", when his multiple medications work, Matthew has between 30 and 50 seizures and when they don't, he has more than 200 seizures. Yet he meets each day engaged, ready to learn and play. Matthew is our inspiration. And this keeps us focused on our mission to deliver novel and more effective therapies for epilepsy and other seizure related disorders.